이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고위험 초기 단계 삼중 음성 또는 호르몬 수용체-로우 양성/HER-2 음성 유방암을 가진 참가자의 다른 항암제와 함께 Patritumab Deruxtecan + Pembrolizumab의 연구 (MK-1022-010, Herthena-Breast-03)

2026년 11월 11일 업데이트: Merck Sharp & Dohme LLC

개방형 무작위 2 상 연구는 카보 플라 틴/파클리탁셀 + 펨브 롤리 주맙과 비교하여 화학 요법과 함께 수술 및 수술 및 보조 펨브 롤리 주 맙에 이어 펨브 롤리 주맙과 비교하여 카보 플라 틴/파클리탁셀 플러스 펨브 롤리 주맙 전후에 투여 된 Patritumab deruxtecan + pembrolizumab의 안전성 및 효능을 평가하기위한 2 상 무작위 2 상 연구. 음성 또는 호르몬 수용체-낮은 양성/인간 표피 성장 인자 수용체 -2 음성 유방암 (Herthena-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

연구 개요

연구 유형

중재적

등록 (추정된)

372

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Taichung, 대만, 407
        • 모병
        • Taichung Veterans General Hospital ( Site 2502)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +886423592525
      • Tainan, 대만, 704
        • 모병
        • National Cheng Kung University Hospital ( Site 2503)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +88662353535
      • Taipei, 대만, 112
        • 모병
        • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 886228970011x1686
      • Seoul, 대한민국, 03080
        • 모병
        • Seoul National University Hospital ( Site 2400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82220720850
      • Seoul, 대한민국, 05505
        • 모병
        • Asan Medical Center ( Site 2401)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82230103217
      • Seoul, 대한민국, 03722
        • 모병
        • Severance Hospital, Yonsei University Health System ( Site 2402)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82222288135
    • California
      • Santa Monica, California, 미국, 90404
        • 모병
        • UCLA Hematology/Oncology - Parkside ( Site 0021)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 424-402-9520
    • Illinois
      • Skokie, Illinois, 미국, 60077
        • 모병
        • Orchard Healthcare Research Inc. ( Site 0006)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 847-568-9932
    • Montana
      • Billings, Montana, 미국, 59102
        • 모병
        • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 406-238-6685
    • Oregon
      • Happy Valley, Oregon, 미국, 97015
        • 모병
        • Northwest Cancer Specialists, P.C. ( Site 8003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 360-944-9889
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • SCRI Oncology Partners ( Site 7000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 844-482-4812
    • Texas
      • Dallas, Texas, 미국, 75246
        • 모병
        • Texas Oncology - DFW ( Site 8000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 214-370-1067
      • Houston, Texas, 미국, 77030
        • 모병
        • Houston Methodist Hospital ( Site 0022)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 713-441-9948
    • Virginia
      • Norfolk, Virginia, 미국, 23502
        • 모병
        • Virginia Oncology Associates (VOA) ( Site 8001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 844-482-4812
      • Córdoba, 스페인, 14004
        • 모병
        • Hospital Universitario Reina Sofia ( Site 1702)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34 957012408
    • Catalonia
      • Badalona, Catalonia, 스페인, 08916
        • 모병
        • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34934978925
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, 스페인, 28027
        • 모병
        • Clinica Universidad de Navarra ( Site 1703)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34913531920

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current leptomeningeal carcinomatosis.
  • Has clinically significant corneal disease
  • Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active HBV and HCV infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

다른 이름들:
  • MK-3475
  • 키트루다®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 탁솔®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 파라플라틴®
실험적: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

다른 이름들:
  • MK-3475
  • 키트루다®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 탁솔®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 파라플라틴®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 아드리아마이신®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 사이톡산®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

다른 이름들:
  • 젤로다®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

다른 이름들:
  • 린파자®
실험적: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

다른 이름들:
  • MK-3475
  • 키트루다®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 탁솔®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 파라플라틴®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 아드리아마이신®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 사이톡산®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

다른 이름들:
  • 젤로다®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

다른 이름들:
  • 린파자®
활성 비교기: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

다른 이름들:
  • MK-3475
  • 키트루다®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 탁솔®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

다른 이름들:
  • 파라플라틴®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 아드리아마이신®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

다른 이름들:
  • 사이톡산®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

다른 이름들:
  • 젤로다®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

다른 이름들:
  • 린파자®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1: Number of Participants Experiencing an Adverse Event (AE)
기간: Up to ~43 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
기간: Up to 21 days

A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
기간: Up to ~30 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
기간: Up to ~30 weeks

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
기간: Up to ~103 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
기간: Up to ~90 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

Up to ~90 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
기간: Up to ~30 weeks

pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Event-Free Survival (EFS)
기간: Up to ~100 months

EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Overall Survival (OS)
기간: Up to ~100 months

OS is defined as the time from randomization to date of death due to any cause.

Up to ~100 months
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
기간: Up to ~100 months

DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Residual Cancer Burden (RCB)
기간: Up to ~30 weeks

RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).

Up to ~30 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

협력자

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 20일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2031년 3월 16일

연구 등록 날짜

최초 제출

2025년 1월 21일

QC 기준을 충족하는 최초 제출

2025년 1월 21일

처음 게시됨 (실제)

2025년 1월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다